
Insmed’s Brinsupri blew past consensus estimates in its first full quarter on the market. Elsewhere, J&J inked pharma’s latest deal with the Trump administration and Madrigal licensed a Pfizer drug.

Insmed’s Brinsupri blew past consensus estimates in its first full quarter on the market. Elsewhere, J&J inked pharma’s latest deal with the Trump administration and Madrigal licensed a Pfizer drug.
Learn 20 ChatGPT prompts for personal development including life planning, habit design, mental clarity, discipline…
California Walnut كما أظهر بحثٌ جديد أن تناول الجوز في وجبة الإفطار يمكن أن يحسّن…
Arab Newswire - Press release distribution to media in MENA/GCC Regions Newswire expands reach with…
In a recent large-scale code modernization initiative, a team used generative AI to convert a clinical data standards library from…
Mehmet Oz, a physician and TV personality, takes office as HHS lays off thousands of staffers and Republicans float potential…
News Jeito Capital has closed its second fund, Jeito II, at more than €1 billion, or about $1.2 billion, giving…
AI drug developer Insilico Medicine has returned to the Hong Kong public markets with an updated IPO prospectus, targeting about $292…
Sign in to your account